← Back to guidelines
Emergency Medicine7 papers

Ischemic hepatitis

Last edited: 4/15/2026

Overview

Ischemic hepatitis is a rare condition characterized by acute liver injury due to severe and persistent hepatic hypoperfusion, often associated with a marked elevation in transaminases levels, typically more than 20 times the normal value. It has a high mortality rate, estimated at around 60%, and can be triggered by various etiologies, including severe cardiac dysfunction 1.

Diagnosis

  • Key Diagnostic Criteria: Rapid and marked elevation in transaminases (>20 times normal) secondary to hepatic hypoperfusion 1.
  • Recommended Tests: Liver function tests (transaminases, bilirubin), imaging studies (CT, MRI) to assess for underlying causes, and possibly liver biopsy in complex cases 1.
  • Grading: Not explicitly detailed in provided abstracts; clinical severity often correlates with the degree of transaminase elevation and presence of complications 1.
  • Management

  • First-Line Treatments: Address and treat the underlying cause (e.g., cardiac dysfunction, shock) 1.
  • Adjunctive Treatments: Supportive care including fluid management, monitoring for liver failure, and potential use of N-acetylcysteine in severe cases, though specific dosing is not detailed 1.
  • Specific Drug Classes: No specific drug classes or doses are mentioned beyond addressing the primary etiology 1.
  • Special Populations

  • Elderly: Increased susceptibility and severity noted in elderly patients, as exemplified by the case report 1.
  • Comorbidities: Severe cardiac dysfunction is highlighted as a significant comorbidity leading to ischemic hepatitis 1.
  • Key Recommendations

  • Prompt identification and treatment of the underlying cause (e.g., cardiac dysfunction) are critical to improve outcomes (Evidence: Expert opinion 1).
  • Monitor liver function closely with serial transaminase levels and bilirubin to guide management (Evidence: Expert opinion 1).
  • Supportive care measures should be implemented early to manage complications and maintain hemodynamic stability (Evidence: Expert opinion 1).
  • References

    1 Aliaga Ramos JJ, Espinoza-Ríos J, Valenzuela Granados V, Pinto Valdivia J, Bussalleu Rivera A. [Fulminating ischemic hepatitis induced by severe cardiac dysfunction: case report]. Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru 2018. link

    Original source

    1. [1]
      [Fulminating ischemic hepatitis induced by severe cardiac dysfunction: case report].Aliaga Ramos JJ, Espinoza-Ríos J, Valenzuela Granados V, Pinto Valdivia J, Bussalleu Rivera A Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru (2018)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG